[1]岳洪武,黄德清.骨康胶囊对老年骨质疏松性髋部骨折内固定患者术后恢复、骨代谢及骨密度的影响[J].医学信息,2021,34(24):73-76.[doi:10.3969/j.issn.1006-1959.2021.24.015]
　YUE Hong-wu,HUANG De-qing.Effects of Gukang Capsule on Postoperative Recovery, Bone Metabolism and Bone Mineral Density in Elderly Patients with Osteoporotic Hip Fracture[J].Medical Information,2021,34(24):73-76.[doi:10.3969/j.issn.1006-1959.2021.24.015]
点击复制

骨康胶囊对老年骨质疏松性髋部骨折内固定患者术后恢复、骨代谢及骨密度的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年24期
页码:
73-76
栏目:
论著
出版日期:
2021-12-15

文章信息/Info

Title:
Effects of Gukang Capsule on Postoperative Recovery, Bone Metabolism and Bone Mineral Density in Elderly Patients with Osteoporotic Hip Fracture
文章编号:
1006-1959（2021）24-0073-04
作者:
岳洪武; 黄德清
（天津市第三中心医院分院骨科，天津 300250）
Author(s):
YUE Hong-wu; HUANG De-qing
(Department of Orthopedics,Branch of Tianjin Third Central Hospital,Tianjin 300250,China)
关键词:
骨康胶囊; 骨质疏松; 髋部骨折; 骨代谢; 骨密度; 骨化三醇
Keywords:
Gukang capsules; Osteoporosis; Hip fracture; Bone metabolism; Bone mineral density; Calcitriol
分类号:
R683
DOI:
10.3969/j.issn.1006-1959.2021.24.015
文献标志码:
A
摘要:
目的 探讨骨康胶囊对老年骨质疏松性髋部骨折内固定患者术后恢复、骨代谢及骨密度（BMD）的影响。方法 选取2017年6月-2019年6月我院接受内固定术的102例老年骨质疏松性髋部骨折患者为研究对象，随机分为观察组52例和对照组50例。对照组术后予以常规治疗，观察组在对照组基础上联合骨康胶囊治疗，比较两组术后恢复时间指标（下床活动时间、术后住院时间、患侧肢体肿胀消退时间、骨折愈合时间），血清骨代谢指标[骨特异性碱性磷酸酶（BALP）、骨钙素（BGP）、Ⅰ型胶原C端肽（PⅠCP）、Ⅰ型胶原N端前肽（PⅠNP）]，股骨颈、大转子、胸椎、腰椎BMD及不良反应发生情况。结果 观察组术后下床活动时间、术后住院时间、患侧肢体肿胀消退时间、骨折愈合时间均短于对照组（P＜0.05）；观察组术后3个月、6个月BALP、BGP、PⅠCP、PⅠNP水平均低于对照组（P＜0.05）；观察组股骨颈、大转子、胸椎、腰椎BMD均高于对照组（P＜0.05）；两组不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论 骨康胶囊可促进骨质疏松性髋部骨折的老年患者内固定术后的病情恢复，调节骨代谢平衡，增加胸腰髋部BMD，安全性较高。
Abstract:
Objective To investigate the Effects of Gukang capsule on postoperative recovery, bone metabolism and bone mineral density (BMD) in elderly patients with osteoporotic hip fracture.Methods Totally 102 elderly patients with osteoporotic hip fractures who underwent internal fixation in our hospital from June 2017 to June 2019 were randomly divided into observation group (52 cases) and control group (50 cases). The control group was treated with routine treatment after operation, and the observation group was treated with Gukang capsule on the basis of the control group. The postoperative recovery time indexes (ambulation time, postoperative hospital stay, limb swelling subsided time, fracture healing time ), serum bone metabolism indexes [bone-specific alkaline phosphatase (BALP), bone Gla protein (BGP), collagen type Ⅰ the C-terminal peptide (PⅠCP), collagen type Ⅰ N-terminal propeptide (PⅠNP)], BMD of femoral neck, greater trochanter, thoracic vertebra, lumbar vertebra, and incidence of adverse reactions were compared between the two groups.Results The ambulation time, postoperative hospital stay, limb swelling subsided time and fracture healing time of the observation group were shorter than those of the control group (P<0.05). The levels of BALP, BGP, PⅠCP and PⅠNP in the observation group at 3 and 6 months after operation were lower than those in the control group (P<0.05). BMDs of femoral neck, greater trochanter, thoracic vertebra and lumbar vertebra in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Gukang capsules can promote the recovery of elderly patients with osteoporotic hip fracture after internal fixation, regulate the balance of bone metabolism, increase the bone density of chest, waist and hip, with high safety.

参考文献/References:

[1]李乐春,井晟,孙晓,等.丹红注射液联合骨肽注射液对老年骨质疏松性髋部骨折术后患者凝血功能及骨代谢指标的影响[J].中国老年学杂志,2019,39(18):4479-4481.[2]赵永杰.老年骨质疏松性髋部骨折患者住院费用的研究[D].广州:广州中医药大学,2017.[3]肖湘,冯凯强,袁宇,等.老年骨质疏松性髋部骨折患者术前下肢深静脉血栓患病率及危险因素分析[J].中华骨科杂志,2015,35(11):1084-1090.[4]蒋尧传,唐志宏,肖荣驰,等.老年骨质疏松性髋部骨折的外科治疗[J].现代预防医学,2011,38(2):377-379.[5]王娜,李旻,王静,等.骨康胶囊用于促进鼻骨骨折恢复的临床研究[J].中国临床药理学杂志,2018,34(21):14-16.[6]王威,廖苏平,危蕾.骨康胶囊辅助治疗老年桡骨远端骨折的临床疗效分析[J].中药材,2015,38(1):193-196.[7]张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识(第三稿,2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.[8]中华医学会骨科学分会创伤骨科学组,中国医师协会骨科医师分会创伤专家工作委员会.成人股骨颈骨折诊治指南[J].中华创伤骨科杂志,2018,20(11):921-928.[9]孙捷.实用微创骨科学[M].北京:北京科学技术出版社,2012:26-29.[10]Gielen E,Bergmann P,Bruyère O,et al.Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club[J].Calcif Tissue Int,2017,101(2):111-131.[11]Tanaka S.Development of osteoporosis drugs -the past,the present and the future[J].Clin Calcium,2017,27(1):137-141.[12]崔丽艳,洪天配.骨转换标志物在骨质疏松症管理中的临床价值[J].中华检验医学杂志,2018,41(4):333-336.[13]梁文娜,李冠慧,林雪娟,等.二至丸调节Sirt1/Runx2信号通路抑制绝经后骨质疏松症肾阴虚证骨代谢失衡的机制探讨[J].中华中医药杂志,2018,33(7):2767-2769.[14]董万涛,吕泽斌,宋敏,等.从脾肾论治骨质疏松症的神经-内分泌-免疫网络平衡机制[J].中国骨质疏松杂志,2015,21(11):1416-1419.[15]申浩,魏戌,谢雁鸣,等.绝经后骨质疏松症骨折危险因素及中医症状相关性研究[J].中国中西医结合杂志,2017,37(1):50-56.[16]余贤斌,孙辽军,胡炜.骨康胶囊治疗绝经后骨质疏松的临床应用及对骨转换标志物水平的影响[J].中华中医药学刊,2015,33(12):157-159.[17]罗贤红,李雄,王蓉辉.温阳补肾法对骨质疏松骨折患者恢复期血清骨钙素、PDGF、sVCAM-1与IGF-1水平影响研究[J].辽宁中医杂志,2016,43(4):768-771.[18]庞坚,王翔,陈元川,等.中药治疗骨质疏松性骨折的组方用药研究[J].时珍国医国药,2015,26(1):238-239.[19]王金鑫,伊丽孜热·亚热买买提,郭虹,等.注射用血栓通(冻干)及三七二醇皂苷、三七三醇皂苷不同配比对体外静脉血栓形成的影响[J].中国药理学通报,2017,33(5):737-739.[20]章轶立,魏戌,谢雁鸣,等.基于整合药理学策略探究补肾活血法治疗骨质疏松症作用机制-以补骨脂-三七药对为例[J].中国实验方剂学杂志,2018,24(21):163-169.[21]骆帝,李金松,肖娟.自拟活血通痹汤在酒精性股骨头坏死治疗中的应用[J].山东医药,2015,55(34):76-77.[22]王长梅,景莉君,韦英杰,等.利用斑马鱼模型评价川续断皂苷Ⅴ和Ⅵ的抗骨质疏松活性[J].中国药科大学学报,2014,45(1):88-91.[23]刘晓艳,董莉,刘亭,等.酢浆草提取物对成骨细胞增殖及分化的影响[J].中国实验方剂学杂志,2015,21(1):117-120.[24]张琪,汪仙阳,马博,等.复方续断总皂苷镇痛抗炎及预防骨质疏松症的实验研究[J].时珍国医国药,2010,21(7):1683-1684.

相似文献/References:

[1]王 忻,赵 毅,朱 悦,等.甲状旁腺激素应用于大鼠脊髓损伤后防治骨质疏松的效果分析[J].医学信息,2018,31(02):54.[doi:10.3969/j.issn.1006-1959.2018.02.019]
　WANG Xin,ZHAO Yi,ZHU Yue,et al.Effect of Parathyroid Hormone on Prevention and Treatment of Osteoporosis after Spinal Cord Injury in Rats[J].Medical Information,2018,31(24):54.[doi:10.3969/j.issn.1006-1959.2018.02.019]
[2]吴玲,李玉兰.个性化心理护理干预应用于骨质疏松的临床效果观察[J].医学信息,2018,31(01):158.[doi:10.3969/j.issn.1006-1959.2018.01.062]
　WU Ling,LI Yu-lan.The Clinical Effect of Personalized Psychological Nursing Intervention on Osteoporosis[J].Medical Information,2018,31(24):158.[doi:10.3969/j.issn.1006-1959.2018.01.062]
[3]刘小花.经皮穿刺椎体成形术治疗老年性骨质疏松性 椎体压缩骨折的疗效分析[J].医学信息,2018,31(05):186.[doi:10.3969/j.issn.1006-1959.2018.05.070]
　LIU Xiao-hua.The Effect of Percutaneous Vertebroplasty in the Treatment of Senile Osteoporotic Vertebral Compression Fracture[J].Medical Information,2018,31(24):186.[doi:10.3969/j.issn.1006-1959.2018.05.070]
[4]杨可佳,孙春华,洪全明,等.经皮椎体成形术治疗骨质疏松性压缩性椎体骨折的疗效观察[J].医学信息,2018,31(17):98.[doi:10.3969/j.issn.1006-1959.2018.17.030]
　YANG Ke-jia,SUN Chun-hua,HONG Quan-ming,et al.Therapeutic Effect of Percutaneous Vertebroplasty for treatment of Osteoporotic Vertebral Compression Fracture[J].Medical Information,2018,31(24):98.[doi:10.3969/j.issn.1006-1959.2018.17.030]
[5]蒋俊良.老年股骨转子间骨折的手术治疗方法[J].医学信息,2018,31(23):58.[doi:10.3969/j.issn.1006-1959.2018.23.017]
　JIANG Jun-liang.Research Progress of Intertrochanteric Fractures of Femurin the Elderly[J].Medical Information,2018,31(24):58.[doi:10.3969/j.issn.1006-1959.2018.23.017]
[6]张 强,杨 帆,陈 康,等.椎体成形术中明胶海绵填塞治疗椎体前壁破损的 OVCFs的临床疗效观察[J].医学信息,2019,32(11):85.[doi:10.3969/j.issn.1006-1959.2019.11.023]
　ZHANG Qiang,YANG Fan,CHEN Kang,et al.Clinical Observation of OVCFs in the Treatment of Anterior Wall Fracture of Vertebral Body with Gelatin Sponge During Vertebroplasty[J].Medical Information,2019,32(24):85.[doi:10.3969/j.issn.1006-1959.2019.11.023]
[7]庞 渊,张 庆,阿伍提·艾克木,等.经皮椎体成形术治疗骨质疏松性椎体压缩性骨折的 疗效分析[J].医学信息,2019,32(11):116.[doi:10.3969/j.issn.1006-1959.2019.11.033]
　PANG Yuan,ZHANG Qing,Awti Aikemu,et al.Therapeutic Effect of Percutaneous Vertebroplasty in the Treatment of Osteoporotic Vertebral Compression Fractures[J].Medical Information,2019,32(24):116.[doi:10.3969/j.issn.1006-1959.2019.11.033]
[8]罗巧彦,凌止发,严宗逊,等.中老年女性骨代谢指标与骨质疏松的相关性研究[J].医学信息,2019,32(17):68.[doi:10.3969/j.issn.1006-1959.2019.17.021]
　LUO Qiao-yan,LING Zhi-fa,YAN Zong-xun,et al.Correlation between Bone Metabolic Markers and Osteoporosis in Middle-aged and Elderly Women[J].Medical Information,2019,32(24):68.[doi:10.3969/j.issn.1006-1959.2019.17.021]
[9]熊义博,刘学员,邓泽熙,等.老年人骨质疏松与动脉硬化的关系[J].医学信息,2019,32(19):106.[doi:10.3969/j.issn.1006-1959.2019.19.033]
　XIONG Yi-bo,LIU Xue-yuan,DENG Ze-xi,et al.Relationship Between Osteoporosis and Arteriosclerosis in the Elderly[J].Medical Information,2019,32(24):106.[doi:10.3969/j.issn.1006-1959.2019.19.033]
[10]常 双,殷晓明,殷兰芳,等.FRAX联合血清学指标评估老年T2DM患者骨质疏松风险的研究[J].医学信息,2022,35(16):76.[doi:10.3969/j.issn.1006-1959.2022.16.017]
　CHANG Shuang,YIN Xiao-ming,YIN Lan-fang,et al.Evaluation of Osteoporosis Risk in Elderly Patients with T2DM by FRAX Combined with Serological Markers[J].Medical Information,2022,35(24):76.[doi:10.3969/j.issn.1006-1959.2022.16.017]

更新日期/Last Update: 1900-01-01